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a b s t r a c t
One of the immune evasion strategies manifested by malignant cells is the downregulation of the
Human Leukocyte Antigen (HLA). HLA Class I (HLA- A, -B, -C) present endogenous peptides including
viral and tumor antigens to cytotoxic T lymphocytes for immune mediated destruction. We have found
the Epstein Barr Virus (EBV) Latent Membrane Protein 2A (LMP2A) to be responsible for this HLA
downregulation in gastric cancer cells. Our results further indicate the Sonic Hedgehog pathway;
primarily Gli1 to bring about the LMP2A mediated decrease in HLA expression.
& 2015 Elsevier Inc. All rights reserved.
Introduction
The components of the cellular immune system have been
known to speciﬁcally recognize and destroy tumor cells and tumor
cells therefore try to escape these cellular immune surveillance
mechanisms (Klein et al., 1960; Restifo et al., 1993). The Major
Histocompatibility Complex (MHC) or the Human Leukocyte Anti-
gens (HLA) are cell surface glycoproteins involved in the antigen
presentation function of immune response. HLA Class Ia molecules
(HLA-A, B and C) resides on the short arm of Chromosome 6 and
are ubiquitously expressed on the surface of most nucleated cells
as a trimolecular complex composed of a 45 kDa polymorphic
heavy chain (α chain), a 12 kDa monomorphic light chain and a 8–
11 amino acid long peptide. The heavy chain polypeptides are
encoded by three closely linked loci, HLA A, HLA B and HLA C that
bind to β2 microglobulin to form a heterodimeric receptor
expressed on the surface of most nucleated cells. They present
intracellular peptides derived from viral and tumor antigens to the
T cell receptor thereby enabling the recognition of target cells by
cytotoxic T lymphocytes (CTL) (Garrido et al., 1997; Zinkernagel
et al., 1996). Importantly, HLA Class I downregulation has been
signiﬁcantly associated with being a frequent event in human
tumors (Dutta et al., 2005; Marincola et al., 2000).
Epstein Barr Virus (EBV) is a ϒ-Herpesvirus that accounts for
5–20% of gastric cancer cases worldwide (Takada, 2000). The virus
has also been implicated to be involved in the development of
various other cancers such as Burkitt's Lymphoma, Hodgkin's
Lymphoma, Nasopharyngeal Carcinoma and Breast Cancer. In all
of the EBV associated malignancies, the virus persists in one of its
three different latent phases where expression of viral genes are
restricted to six EBV nuclear antigens (EBNA-1,-2, -3A, -3B, -3C,
and –LP), three latent membrane proteins (LMP1, 2A and 2B), two
relatively abundant small, non-coding, non-polyadenylated
uncapped RNAs (EBER1 and EBER2), and less abundant BamHI A
rightward frame transcripts (BARTs), but in different combina-
tions. In EBV associated gastric cancer, the virus manifests Latency
I where the expression of viral genes is restricted EBNA I, EBERs,
LMP2A and BamH1 rightward framed transcripts (Longnecker
et al., 2013). Previous studies (Frisan et al., 1996; Shen et al.,
2001) have reported HLA defects in the HLA Class I- antigen
processing and presentation in EBV-associated Burkitt's lym-
phoma and nasal Natural Killer (NK) cell/T-cell carcinoma. Further-
more, a number of earlier reports (Diepstra et al., 2005; Huang
et al., 2012; Su et al., 2013) have shown several EBV associated
carcinomas including Hodgkin's Lymphoma and Nasopharyngeal
Carcinoma to display downregulation of the HLA Class 1 loci
(Diepstra et al., 2005; Huang et al., 2012; Sengupta et al., 2006;
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Su et al., 2013). Moreover, earlier studies from our group have also
shown EBV associated gastric cancer to be associated with HLA
Class I downregulation (Dutta et al., 2006). We therefore further
proceeded to pin point the EBV latency I gene that may be bringing
about the decrease HLA Class Ia expression in gastric cancer cells.
Self renewal pathways are important in the maintenance and
progression of the tumors. One of the principal self-renewal
pathways is the Sonic Hedgehog pathway. Sonic Hedhehog path-
way functions during normal embryogenesis to regulate tissue
morphogenesis and patterning. Studies by Port et al. (2013) have
indicated that sustained or aberrant activation of this pathway in
adult tissues facilitated cancer progression and cancer stem cell
maintenance. Moreover, previous reports (Beachy et al., 2004)
have associated dysregulation of the Hedgehog pathway in a range
of malignancies, including those of the skin, breast, lung, brain,
prostate and digestive tract. Hedgehog signaling is initiated by
binding of a Hedgehog ligand to Patched (PTCH1), a transmem-
brane protein that represses the activity of Smoothened (SMO), a
protein that displays similarities to G protein-coupled receptors. In
response to Hedgehog ligand binding, PTCH1 repression of SMO is
relieved, and the activity of three GLI transcription factors (GLI1, 2,
3) is induced through altered protein processing and/or transcrip-
tional upregulation. While GLI1 is a transcriptional activator, GLI3
is a repressor; GLI2 can either activate or repress. Hedgehog
stimulates the expression of a variety of downstream effectors
which affect several carcinogenic parameters such as cell growth,
survival, differentiation, angiogenesis and cell motility. We there-
fore proceeded to investigate the involvement of the hedgehog
pathway in another tumorigenic property, HLA downregulation.
Earlier reports have pointed out EBV positive gastric cancer cells
SNU719 to decrease HLA ABC expression (Dutta et al., 2006). Since
LMP2A and EBERs are the limited genes expressed in EBV
associated gastric cancer, we further tried to determine whether
this HLA Class Ia downregulation is brought about by LMP2A or
EBERs or both. Our results indicated that EBV LMP2A and not
EBERs decreases HLA ABC expression. Moreover because previous
studies highlight the role of EBV LMP2A in activating the Sonic
Hedgehog pathway (Port et al., 2013), we further tried to deter-
mine whether LMP2A may be bringing about HLA ABC down-
regulation via the Sonic Hedgehog pathway. Our results clearly
implicated EBV LMP2A to bring about Sonic Hedgehog pathway
especially Gli1 mediated decrease in HLA ABC expression.
Results
EBV LMP2A decreases HLA ABC expression
Having known that EBV positive Korean gastric cancer cells do
decrease HLA ABC expression (Dutta et al., 2006), we ﬁrst
proceeded to determine the EBV latent gene which may be
bringing about this effect. We targeted the two main genes
detected in most gastric cancer samples viz; LMP2A and EBERs.
EBV negative gastric cancer cells AGS were stably transfected with
pcDNA-LMP2A, pREP7-EBERs or doubly transfected with LMP2A
and EBERs. The pcDNA/pREP7 stably transfected cells were used as
vector controls. The fold change in expression of LMP2A and EBERs
in stable clones of AGS-LMP2A, AGS-EBERs, AGS-LMP2AEBERs and
EBV positive gastric cancer cells SNU719 cells relative to AGS
vector control cells is depicted in Fig. 1A. Protein level expression
of LMP2A was also estimated in SNU719, AGS-LMP2A and AGS-
LMP2AEBERs compared to AGS Control cells (Fig. 1B). Additionally,
LMP2A was stably introduced into non-tumorigenic cell Human
Embryonic Kidney 293 (HEK293) and its expression was studied
both at the mRNA and protein levels in order to validate transfec-
tion (Fig. 1A and B). In order to determine the effect of EBV
oncogenes on HLA expression, AGS-LMP2A, AGS-EBERs, AGS-
LMP2AEBERs as well as SNU719 cells were analyzed for HLA ABC
expression compared to AGS control cells. It was observed that
while AGS-LMP2A and AGS-LMP2AEBERs displayed a decreased
HLA Class I expression as also observed in EBV positive SNU719
cells, AGS-EBERs showed an expression similar to control cells
(Fig. 1C). Quantitation of the above results showed SNU719, AGS-
LMP2A and AGS-LMP2AEBERs to have a median value of
3.4370.74, 11.9771.25, 8.8270.2 respectively. AGS-EBERs on
the other hand displayed a median of 23.7172 compared to
AGS control cells that display a median of 25.71 for HLA ABC
expression (Fig. 1C) indicating EBV LMP2A and not EBERs to be
responsible for HLA Class Ia downregulation in gastric cancer cells.
Moreover, HEK-LMP2A also displayed a decreased HLA-ABC
expression compared to HEK Control cells (Fig. 1C). Furthermore
RT-PCR analysis was performed to determine mRNA expression of
HLA A, HLA B and HLA C and also β2 microglobulin in SNU719,
AGS-LMP2A and HEK-LMP2A compared to their respective control
cells. HLA A, B and C showed a decreased mRNA expression in
LMP2A expressing cells relative to AGS and HEK controls (Fig. 1D).
Similar results were also obtained in SNU719 cells that constitu-
tively express the EBV oncogenes when compared to EBV negative
AGS cells (Fig. 1D). In order to further conﬁrm the role of EBV
LMP2A in bringing about the HLA Class I downregulation, LMP2A
was subjected to time dependent siRNA mediated knockdown in
positive control gastric cancer cells SNU719. Transfection of
SNU719 with 20 nM of LMP2A siRNA caused a time dependent
increase in HLA ABC protein expression as well as in the individual
HLA Class I gene expression in SNU719 cells (Fig. 1E and F) thereby
authenticating the involvement of EBV LMP2A in decreasing HLA
ABC expression. Moreover, introduction of mutant LMP2A (pSG/
LMP2A Y74/85 F) into AGS cells manifested a marginal increase in
HLA ABC expression thereby further validating the role of EBV
LMP2A in HLA Class 1a downregulation (Fig. 1G). Expression of
mutant LMP2A in AGS cells was conﬁrmed by immunoblotting
analysis using LMP2A antibody (Supplementary Fig. 1).
EBV LMP2A activates the Sonic Hedgehog pathway in gastric cancer
cells
EBV-LMP2A is known to activate the Sonic Hedgehog pathway
in Nasopharyngeal carcinoma which imposes stem-like character-
istics to these cells. Because immune evasion is one of the
properties often associated with cancer stem cells (Nahas et al.,
2012; Schatton and Frank, 2009), we wanted to ﬁnd out whether
the Hedgehog pathway may also contribute to HLA Class I down-
regulation in our cellular systems. Sonic Hedgehog pathway
activation in LMP2A expressing gastric cancer cells (SNU719 and
AGS-LMP2A) was evaluated by determining the mRNA expression
levels of Sonic Hedgehog pathway genes in these cells compared
to their respective vector controls by Quantitative Real Time PCR. It
was observed that LMP2A signiﬁcantly upregulated the mRNA
expression of Sonic Hedgehog (SHH), Patched (Ptc), Smoothened-1
(Smo-1) and Gli1as observed by Quantitative Real Time PCR. Gli3
shows a decreased expression in AGS-LMP2A and SNU719 relative
to AGS control cells (Fig. 2A). Immunoblotting experiments also
reveal an increased Gli1 and decreased Gli3 expression in LMP2A
expressing cells (Fig. 2B). Additionally, LMP2A expressing HEK293
cells also manifested an elevated Sonic Hedgehog pathway both at
the transcript as well as protein levels (Fig. 2A and B). To further
conﬁrm the Hedgehog pathway activation in LMP2A expressing
gastric cancer cells, the transcript level of Gli1 and Gli3 was
determined at 24, 48 and 72 h post LMP2A knockdown in EBV
positive SNU719. Indeed LMP2A siRNA decreases the transcript
level expression of Shh, Ptc, Smo-1 and Gli1 and increased the
expression of Gli3 in a time dependent manner (Fig. 2C). The
A. Deb Pal, S. Banerjee / Virology 484 (2015) 22–32 23
Fig. 1. EBV LMP2A decreases HLA ABC expression. (A) Stable expression of LMP2A/EBERs in AGS-LMP2A, AGS-EBERs, AGS-LMP2AEBERs, HEK-LMP2A and also EBV positive
Korean gastric cancer cell SNU719 was conﬁrmed using Quantitative RT-PCR. (B) Protein expression of LMP2A in AGS-LMP2A, AGS-LMP2AEBERs, HEK-LMP2A and SNU719
compared to their respective control cells. Bar graph depicts the densitometry quantiﬁcation of relative expression levels of LMP2A. Results are represented as mean7s.e.m.
of triplicate experiments. (C) Flow cytometric analysis of protein expression of HLA ABC in SNU719, AGS-LMP2A, AGS-EBERs and AGS-LMP2AEBERs compared to AGS control
cells. HLA ABC expression in HEK-LMP2A compared to HEK293 vector control cells was also determined using ﬂow cytometry. Quantitation of results was performed by
measuring median values using Cell Quest Pro software. (D) RT-PCR estimation of relative change in mRNA expression levels of HLA A, HLA B, HLA C and β2 Microglobulin in
SNU719 and AGS-LMP2A and HEK-LMP2A. (E) HLA ABC expression upon treatment of SNU719 cells with 20 nM of LMP2A siRNA for 24, 48 and 72 h. Histogram plot indicates
an increase in HLA ABC expression with a concomitant decrease in LMP2A expression upon siRNA mediated knockdown of LMP2A in SNU719 at 72 h. (F) Quantitative Real
Time PCR to determine relative transcript level expression of HLA A, B and C upon siRNA mediated inhibition of LMP2A in SNU719. (G) HLA ABC expression upon introduction
of mutant LMP2A (Y74/85F) into AGS cells. Data represents an average of n¼3 independent experiments. *, ** and *** denote P value o0.05, o0.005 ando0.001
respectively.
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Fig. 2. EBV LMP2A activates the Sonic Hedgehog pathway. (A) Quantitative RT-PCR of Sonic Hedgehog pathway genes in SNU719, AGS-LMP2A and HEK-LMP2A relative to
AGS and HEK293 control cells respectively. (B) Immunoblotting experiments to determine Gli1 and Gli3 levels in AGS Control, SNU719, AGS-LMP2A and HEK293 Control and
HEK-LMP2A. Bar graph depicts the densitometry quantiﬁcation of relative expression levels of Gli1 and Gli3. (C) Real Time PCR analysis of Sonic Hedgehog pathway genes
upon siRNA mediated knockdown of LMP2A expression in SNU719 cells at 24, 48 and 72 h respectively. (D) Protein levels of Gli1 and Gli3 in SNU719 cellsþLMP2A siRNA
(72 h). Gli1 expression in AGSþLMP2A siRNA (72 h) relative to AGS control cells. Results are represented as mean7s.e.m. of 3 individual experiments. (E) Quantitative Real
Time PCR indicating Gli1 and Gli3 expression in AGS cells transfected LMP2A siRNA. scr siRNA indicates scrambled siRNA.
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Fig. 3. Decrease in HLA ABC expression upon LMP2A expression is via the Hedgehog pathway. (A) Effect of downstream modulator Gli1 upon inhibiting the Shh pathway in
SNU719 cells using forskolin. Dose and time response of HLA ABC expression when SNU719 cells are treated with Forskolin compared to untreated cells. Flow cytometric
analysis of SNU719 cells treated with Forskolin (30 μM, 48 h). (B) Gli1 expression in AGS-LMP2A cells upon inhibiting the Shh pathway using forskolin. Dose and time
response of HLA ABC expression when AGS-LMP2A cells are treated with Forskolin compared to untreated cells. Flow cytometric analysis of AGS-LMP2A cells treated with
Forskolin (30 μM, 48 h). (C) Effect of Forskolin on Hedgehog pathway gene Gli1 in a dose and time dependent manner in HEK-LMP2A. Dose and time response of HLA ABC
expression when HEK-LMP2A cells are treated with Forskolin compared to untreated cells. Flow cytometric analysis of HEK-LMP2A cells treated with Forskolin (30 μM, 48 h).
(D) Quantitative RT-PCR of HLA A, B and C expression of SNU719þForskolin relative to untreatedSNU719. (E) Quantitative RT-PCR of HLA A, B and C expression of AGS-
LMP2AþForskolin relative to untreated AGS-LMP2A. (F) mRNA expression levels of HLA A, B and C in HEK-LMP2AþForskolin relative to untreated HEK-LMP2A. The mean
values7standard error obtained from atleast three independent experiments are shown. *, ** and *** denote P value o0.05, o0.005 ando0.001 respectively.
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protein levels of Gli1 and Gli3 in SNU719 cells post 72 h of LMP2A
siRNA treatment further displays a decreased Gli1 without any
signiﬁcant change in Gli3 compared to untreated SNU719 cells
(Fig. 2 D). Moreover, treatment of non-LMP2A expressing gastric
cancer cells (AGS) with LMP2A siRNA manifested no marked
change in Gli1 expression thereby conﬁrming the speciﬁcity and
efﬁcacy of LMP2A siRNA treatment (Fig. 2E).
Decrease in HLA ABC expression upon LMP2A expression is via the
Hedgehog pathway
In order to estimate whether the Hedgehog pathway may also
contribute to HLA Class I downregulation, LMP2A expressing
gastric cancer cells (SNU719 and AGS-LMP2A) were treated with
Hedgehog pathway inhibitor Forskolin. Forskolin increased HLA
ABC expression in a dose and time dependent manner in both
SNU719 (Fig. 3A) and AGS-LMP2A (Fig. 3B). Furthermore inhibition
of the Sonic Hedgehog pathway in HEK LMP2A cells also displayed
increased HLA ABC expression (Fig. 3C). The efﬁcacy of Forskolin in
inhibiting the Sonic Hedgehog pathway was checked by estimat-
ing the expression of Gli1 in SNU719, AGS-LMP2A and HEK-LMP2A
at the applied dosage and time (Fig. 3A–C). Quantitative RT-PCR
analysis of HLA-A, B and C also showed a decreased expression of
the HLA Class Ia mRNAs in LMP2A expressing gastric cancer
(Fig. 3D and E) as well as HEK293 cells (Fig. 3F) relative to their
respective controls.
LMP2A dependent HLA ABC downregulation is manifested by
Hedgehog downstream mediators
LMP2A has also been shown to activate other self-renewal
pathways such as the Notch pathway, the Wnt/β catenin pathway
and the PI3K/Akt pathways in epithelial cells. Interestingly, treat-
ment with Notch pathway inhibitor ϒ-secretase inhibitor (GSI),
Wnt/β catenin pathway inhibitor PNU74654 and PI3K/Akt inhibi-
tor LY294002 showed no indicative increase in HLA ABC expres-
sion in SNU719 cells (Fig. 4A), AGS LMP2A cells (Fig. 4B) and HEK-
LMP2A cells (Fig. 4C) thereby indicating the speciﬁcity of the Sonic
Hedgehog pathway in affecting HLA Class Ia expression. The
efﬁcacy of inhibition of the Notch, Wnt and PI3K pathway by their
respective inhibitors in SNU719 cells was evaluated by estimating
the protein levels of the downstream pathways effectors viz;
Notch Intracellular Domain (NICD), β catenin and p-Akt respec-
tively in the SNU719 treated cells relative to untreated SNU719. A
decrease in expression of NICD (Supplementary Fig. 2A), β catenin
(Supplementary Fig. 2B) and p-Akt (Supplementary Fig. 2C) was
observed upon treatment with their respective inhibitors for 48 h.
The Hedgehog pathway activates downstream genes via its tran-
scriptional activator Gli1. Silencing of Gli1 in LMP2A expressing
cells using siRNA mediated approach also showed an increased
HLA ABC expression at the protein as well as the RNA level in both
SNU719 (Fig. 4D) and AGS-LMP2A (Fig. 4E). Decrease in Gli1
expression with increasing time of siRNA treatment conﬁrms
Gli1 knockdown in these cells (Fig. 4D and E). Moreover, LMP2A
expressing HEK293 cells also displayed an increased HLA class Ia
expression when subjected to siRNA mediated knockdown of Gli1
(Fig. 4F).
LMP2A dependent HLA ABC downregulation is Gli1 speciﬁc
While knocking down Gli1 increased HLA ABC expression
(Fig. 4), silencing Gli3 another downstream mediator of the
Hedgehog pathway showed no signiﬁcant change in HLA ABC
expression both at the protein and the transcript levels in LMP2A
expressing gastric cancer cells (Fig. 5A and B) as well as HEK-
LMP2A cells (Fig. 5C). In order to further conﬁrm the above
phenomenon, Gli1 cDNA was introduced into AGS and HEK293
cells. A decrease in HLA ABC expression with increasing duration
of treatment was observed at both the protein as well as at the
transcript levels post Gli1 transfection (Fig. 5D and E). Therefore,
HLA ABC downregulation in LMP2A expressing cells is Gli1
dependent. Various Transcription Factors (TRFs) including NFКB,
CIITA and RFX5 are known to bind the Class Ia promoter and
regulate its expression (Garrido et al., 1997; Van den Elson et al.,
1998). Determination of the expression levels of these TRFs
showed their decreased protein expression in LMP2A expressing
gastric cancer cells SNU719 and AGS LMP2A (Supplementary
Fig. 3). Interestingly, treatment of SNU719 and AGS LMP2A cells
with Forskolin and Gli1 siRNA increased the expression NFКB,
CIITA and RFX5 proteins compared to untreated control cells
(Supplementary Fig. 4A and 4B). Therefore, LMP2A mediated Gli1
dependent reduction in expression of HLA Class Ia TRFs may be
responsible for decreased HLA ABC expression and hence an
increased capacity of immune evasion.
Discussion
To be an oncogenic pathogen, EBV must prevent the cells from
becoming a target for killing by the immune system (immune
evasion). Evolutionary studies strongly suggest that the virus and
the host have coevolved over millions of years, achieving a ﬁne
balance between viral persistence and immune control. Stable
existence is achieved through regulated cycles of latent infection
and chronic reactivation. This latent infection and persistency is
controlled by EBV speciﬁc cytotoxic T lymphocytes (CTLs). The loss
of CTLs either at the target level or the effector level can severely
compromise the host's ability to control outgrowth of EBV infected
tumor cells (Khanna and Burrows, 2000). Viruses like Human
Papilloma virus (HPV), Human Cytomegalovirus (HCMV) and
Human Immunodeﬁciency virus (HIV) use various mechanisms
to modify the maturation, assembly and export of HLA Class I
molecules (Fruh et al., 1999; Tortorella et al., 2000). Although
defects in proteins responsible for antigen presentation such as
Transported Associated proteins TAP1 and 2 have been reported to
play a crucial role in various EBV associated carcinomas especially
Burkitt's lymphoma (Khanna and Burrows, 2000; Khanna et al.,
1994); reports also point out that LMP2A epitopes can be pro-
cessed and presented by TAP independent mechanism (Khanna
et al., 1996). Downregulation or complete loss of HLA Class Ia
expression has been reported in a variety of human tumors and
has been proposed to be a mechanism to evade immune surveil-
lance and cancer progression (Garrido et al., 1997). Furthermore
reports from our group have shown EBV infected gastric cancer
cells to display reduced HLA Class Ia expression (Dutta et al.,
2006). Our present study points out the EBV latency gene (EBV
LMP2A) that is responsible for the observed HLA ABC down-
regulation in gastric cancer cells.
The contribution of dysregulated cell signaling pathways to the
etiology of this cancer especially immune evasion is not very well
deﬁned. Here we show the Sonic Hedhehog pathway principally
Gli1 to have a role in LMP2A mediated HLA ABC downregulation. It
is estimated that upwards of 25% of all cancers require autocrine
or paracrine Hedgehog signaling plays an important role to sustain
tumor cell growth and survival (Lum and Beachy, 2004). Moreover
LMP2A was shown to activate stemmness genes; Bmi-1 and EZH2
in a Sonic Hedhehog dependent manner in Nasopharyngeal
Carcinoma (Port et al., 2013). Stem cells in addition to its self-
renewal properties that aid in cancer progression have also been
shown to confer immune suppression and bring about overall
immune survival (Nahas et al., 2012; Schatton and Frank, 2009).
We therefore explored the effect of LMP2A induced Sonic
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Fig. 4. LMP2A dependent HLA ABC downregulation is manifested by Hedgehog downstream mediators. (A–C) HLA ABC expression upon treating SNU719 (A), AGSLMP2A (B) and
HEK LMP2A (C) cells with GSI, PNU74654 and LY294002. (D) Time dependent response of HLA ABC expression when SNU719 cells are treated with 20 nM Gli1 siRNA relative
to untreated cells. Flow cytometric analysis of SNU719 cells treated with Gli1 siRNA for 72 h. Quantitative RT-PCR of HLA A, B and C expression in SNU719þGli1 siRNA
relative to untreated SNU719 cells. (E) Time dependent response of HLA ABC expression when AGS-LMP2A cells are treated with Gli1 siRNA relative to untreated cells. Flow
cytometric analysis of AGS-LMP2A cells treated with Gli1 siRNA for 72 h. Quantitative RT-PCR of HLA A, B and C expression of AGS-LMP2AþGli1 siRNA relative to untreated
AGS-LMP2A. (F) Time dependent response of HLA ABC expression when HEKþLMP2A cells are treated with 20 nM Gli1 siRNA relative to untreated cells. Flow cytometric
analysis of HEK-LMP2A cells treated with Gli1 siRNA for 72 h. Quantitative RT-PCR of HLA A, B and C expression in HEK-LMP2AþGli1 siRNA relative to untreated HEK-LMP2A.
Results are represented as mean7s.e.m. of 3 individual experiments.
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Fig. 5. LMP2A dependent HLA ABC downregulation is Gli1 speciﬁc. (A–C) HLA Class Ia expression upon treating SNU719 (A), AGS LMP2A (B) and HEK-LMP2A (C) with Gli3
siRNA. (D–E) HLA ABC expression upon introduction of Gli1 cDNA into AGS (D) and HEK293 cells (E). Flow cytometric analysis of AGS (D) and HEK293 (E) cells when treated
with Gli1 cDNA for 72 h. Transcript level expression of HLA-A, B and C mRNA in AGSþGli1 (D) and HEK293þGli1 (E) at 24, 48 and 72 h relative to their respective vector
control cells. The mean values7standard error obtained from atleast three independent experiments are shown. *, ** and *** denote P value o0.05, o0.005 ando0.001
respectively.
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Hedgehog pathway on HLA Class Ia expression. We indeed found
LMP2A to cause Sonic Hedgehog pathway mediated HLA Class Ia
downregulation as inhibition of this pathway using Forskolin
increased HLA ABC expression. Furthermore inhibition of other
important self-renewal pathways such as the Notch, Wnt/β
catenin and the PI3K/Akt pathway had no signiﬁcant effect on
HLA ABC expression indicating the speciﬁcity of the Hedgehog
pathway in HLA Class Ia downregulation. Moreover this decrease
in classical Class Ia expression was found to be Gli1 mediated since
silencing Gli1 in LMP2A expressing gastric cancer cells also
increased HLA ABC expression. Previous reports reveal the HLA
Class 1a genes to be under both constitutive as well as inducible
activation by several TRFs. NFКB is a TRF that has been shown to
constitutively activate the Class 1a promoter (Girdlestone, 1996).
Several other TRFs such as CIITA and RFX5 although previously
reported to bring about MHC Class II activation have now also
been associated with inducible HLA Class I activation (Martin et al.,
1997; van den Elson et al., 1998). Our studies indicate LMP2A
expressing gastric cancer cells to decrease the expression of the
above TRFs. Hence it is possible that LMP2A may utilize the Sonic
Hedgehog mediator Gli1 to bring about HLA ABC downregulation
via decreased expression of some important constitutive and
inducible TRFs.
Studies of EBV LMP2A till date have implicated this protein in
cell migration and invasion (Banerjee et al., 2013; Fotheringham
et al., 2012; Lan et al., 2012; Pal et al., 2014) anchorage indepen-
dent growth (Scholle et al., 1999), Epitheilial Mesenchymal Transi-
tion (EMT) (Kong et al., 2010) and also apoptotic resistance
(Fukuda and Longnecker, 2004). Our present report highlights
the role of LMP2A to induce Sonic Hedgehog pathway dependent
HLA Class Ia downregulation in Gastric Cancer cells. This study
therefore identiﬁes a novel function of LMP2A which along with
the earlier explored functionalities may help in generating new
approaches in combating EBV induced malignancies.
Materials and methods
Materials
Forskolin, PNU74654 and LY294002 and were purchased from
Abcam (Cambridge, UK), Sigma Aldrich (St. Louis, MO) and
Calbiochem (Merck Ltd, USA) respectively. ϒ secretase inhibitor
(GSI) and G418 were purchased from Calbiochem (Merck Ltd,
USA). All of the above chemicals were dissolved in DMSO and used
in the required dosage. The HLA ABC antibody was obtained from
BD Biociences (San Jose, CA). The Gli1 and Gli3 primary antibodies
were obtained from Cell Signaling Technology (Beverly, MA) and
Abcam (Cambridge, UK) respectively whereas NFКB, CIITA and
RFX5 primary antibodies were purchased from Santa Cruz (Cali-
fornia, USA). β-actin primary antibody and anti-rabbit and anti-
mouse horseradish peroxidase (HRP)-conjugated secondary anti-
bodies were purchased from Cell Signaling Technology
(Beverly, MA).
Cell culture
Human gastric cancer cell lines, EBV-negative AGS and EBV-
positive SNU719 (Korean Cell Line Bank) were maintained in RPMI
1640 (Gibco, Carlsbad, CA) supplemented with 10% (v/v) heat
inactivated fetal bovine serum (FBS) in 5% CO2 humidiﬁed atmo-
sphere at 37 1C. Human Embryonic Kidney 293 (HEK 293) cell was
grown in DMEM (Gibco, Carlsbad, CA).
DNA constructs and transfection
LMP2A cDNA and LMP2A ITAM mutant plasmid (pSGY74/85F)
was kindly provided by Prof. R. Longnecker, (Northwestern Uni-
versity, Chicago, USA). LMP2A cDNAwas cloned into the EcoR1 site
of the vector pcDNA (Invitrogen, Carlsbad, CA, USA) to obtain the
plasmid LMP2A/pcDNA. The EBERs-DNA fragment including the
promoter region was generated from the EBV-DNA present in the
prototype B95-8 strain by PCR ampliﬁcation (50-ATATGTC-
GACGTCTCGGAGCTCCTAGGTCAGAC-30 and 50-ATATGTCGACATG-
CATATACAGTCAGCATATG-30). The 1171 bp EBERs open reading
frame (ORF) fragment was inserted into the SalI-digested pREP7
vector (Invitrogen, Carlsbad, CA) to produce EBERs/pREP7. AGS-
LMP2AEBERs clones were generated by doubly transfecting AGS
with pREP7 vector containing EBERs and pcDNA containing the
LMP2A cDNA. The plasmids were transfected into the cells using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Stable clones of
transfectants expressing only vector pcDNA and LMP2A were
selected in medium containing 800 mg/mL of G418 (Gibco, Carls-
bad, CA). AGS clones stably expressing EBERs were selected in a
media containing containing 400 mg/mL of Hygromycin (Invitro-
gen, Carlsbad, CA) whereas stable clones expressing both LMP2A
and EBERs were selected with 400 mg/mL of hygromycin and
800 mg/mL of G418. The pll3.7 empty vector and pll3.7-Gli1vector
construct was a kind gift from Prof. Fritz Aberger (University of
Salzburg, Austria).
RT-PCR and quantitative real time PCR
Total RNA was extracted using Tripure isolation reagent (TRI-
ZOL, Roche, Mannheim, Germany) and quality assayed using RNA
gel electrophoresis as well as spectroscopy (Eppendorf BioPhot-
ometer, Hamburg, Germany). 3 μg of RNA was subsequently
treated with RNAse free DNAse (DNAfreeTM Ambion, Austin, TX)
and reverse transcribed for 90 min at 42 1C using random hexamer
primers and M-MuLV reverse transcriptase (Fermentas, Burling-
ton, Ontario).
Quantitative RT-PCR was performed using SYBR Green core PCR
reagents (Applied Biosystems, Framingham. MA) and HPRT1 as the
endogenous control. The qRT–PCR reactions and analyses were
carried out in 7500 Sequence Detection System (Applied Biosys-
tems). The primer sequences were as follows: (a) HLA A; 50-
CCTGGGCAGTCGCACTGC-30 (sense primer) and 50-GATTCTCCCCA-
GACGCCGAG-30 (antisense primer); (b) HLA B; 50-GGACAGCCA-
GACCAGCAACA-30 (sense primer) and 50-GATTCTCCCCAGACG-
CCGAG-30 (antisense primer); (c) HLA C; 50-TCAGAGCCCTGGG-
CACTGTT-30 (sense primer) and 50-GATTCTCCCCAGACGCCGAG-30
(antisense primer); (d) β2 microglobulin; 50-TGAAGCTGACAG-
CATTCG-30 (sense primer) and 50-TGCGGCATCTTCAAACCTCC-30
(antisense primer); (e) Gli1; 50-GTTCACATGCGCAGACACACT-30
(sense primer) and 50-CCTCGTGCTCACACATGTATGG-30 (antisense
primer); (f) Gli3; 50-GGACCCCAGGAATGGTTACATG-30 (sense pri-
mer) and 50-CGTAATGGTAACGGCCCTCAT-30 (antisense primer);
(g) Ptch1; 50-CCTCACGTCCATCAGCAATG-30 (sense primer) and 50-
GCAGGAAAAATGAGCAGAACCA-30 (antisense primer); (h); Smo-1;
50-CCAGGACATGCACAGCTACATC-30 (sense primer) and 50-CAAA-
GAAGCACGCATTGACGTA-30 (antisense primer); (i); Shh; 50-
GAGCGGACAGGCTGATGACT-30 (sense primer) and 50-CTCGG-
TCACCCGCAGTTTCA-30 (antisense primer).
Western blot analysis
Cells were harvested, lysed in Nonidet P-40-lysis buffer [20 mM
Tris–HCl (pH 8.0), 137 mM NaCl, 10% glycerol, 1% NonidetP-40,
2 mM EDTA, 200 mM Na3VO4, 100 mM phenylmethylsulfonyl ﬂuor-
ide, protease inhibitor cocktail (Roche, Mannheim, Germany) and
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phosphatase inhibitor (Roche, Mannheim, Germany) for 30 min on
ice, and centrifuged at 16,000 g for 5 min at 4 1C and the super-
natant was collected. Equal amounts of protein (25–50 mg) were
subjected to 10% SDS-polyacrylamide gel electrophoresis and
electrotransferred onto nitrocellulose membrane (GE Healthcare,
USA). The protein blot in the membrane was blocked with 5% BSA
in TBS containing 0.1% Tween 20 (Sigma Chemical Co., St. Louis,
MO) for 1 h at room temperature. Primary antibodies as indicated
were incubated with membranes for 4 1C overnight, and the
membranes were washed in TBS-T, probed with horseradish
peroxidase-conjugated secondary antibodies (Cell Signaling Tech-
nology, Beverly, MA) for 1 h (1:3000 dilution in TBS-T), and then
washed with TBS-T. The antibody-bound protein bands were
detected with enhanced chemiluminescence reagent (Amersham
Biosciences, Pittsburgh, PA) and photographed using VersaDoc
chemiluminescence detector and Quantity ONE software (Bio-
Rad, Hercules, CA).
RNA interference
The sequence of siRNA for inhibiting expression of LMP2A
mRNA was identical to that previously reported (Shin et al.,
2010). Gli1 and Gli3 siRNAs were obtained from Santa Cruz
(California, USA). A controlled scrambled sequence was also used
(Sigma, USA).The siRNAs were transfected using Lipofectamine
2000 (Invitrogen, UA) and the cells assayed for silencing at
different time points using independent sets of transfection
experiments.
Cell surface analysis of HLA ABC
1105 cells in 100 mL PBS supplemented with 5% PBS were
incubated with allophycocyanin (APC) conjugated anti-HLA ABC
monoclonal antibody for 20 min in dark at 4 1C. The amount of
antibody used was as per manufacturer's instructions. The samples
were then washed twice with PBS, resuspended in PBS and
submitted to Fluorescence Activated Cell Sorting (FACS) Analysis
using FACS Calibur (Becton Dickinson, San Jose, CA). The results
were analyzed using Cell Quest Pro software (B.D. Biosciences, San
Jose, CA).
Statistical analysis
Results obtained from all experiments were reported as the
mean7s.e.m. The signiﬁcance of the analyzed data was calculated
by standard student's t-test. The gene expression levels were
compared by unpaired two-tailed t-test. Only Po0.05 was con-
sidered statistically signiﬁcant.
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